clinical trials oncology
Developing Clinical Trials for Oncology Part 3: Growth Trends in Oncology Therapeutics
September 22 by Pharmaceuticals & Biotechnology EditorMore than ever clinical trials are more complicated and more difficult to run. Denis Mir, Senior Manager of Clinical Operations in Oncology at Eisai Global Clinical Development, shares his though...
Developing Clinical Trials for Oncology Part 4: The Recipe for Success
September 22 by Pharmaceuticals & Biotechnology EditorBiotechs have fuelled the oncology therapeutic area with many sucessful drugs. Denis Mir, Senior Manager of Clinical Operations in Oncology at Eisai Global Clinical Development, shares his though...
Developing Clinical Trials for Oncology Part 1: Increasing Patient Enrollment
September 13 by Pharmaceuticals & Biotechnology EditorEngaging patients in clinical trials is major hurdle for clinical research. Denis Mir, Senior Manager of Clinical Operations in Oncology at Eisai Global Clinical Development, provides a fr...
Controversy Around Clinical Trials Approval Endpoints - US Regulatory History of Avastin at Optimising Clinical Development in Oncology
January 05 by Pharma IQ NewsGary Acton, CMO from Antisoma will explore the challenges the contemporary controversy around clinical trials approval faces at Optimising Clinical Development in Oncology, 15th-16th March 2011 in Lon...
